181 related articles for article (PubMed ID: 11049017)
21. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Shen ZX; Chen GQ; Ni JH; Li XS; Xiong SM; Qiu QY; Zhu J; Tang W; Sun GL; Yang KQ; Chen Y; Zhou L; Fang ZW; Wang YT; Ma J; Zhang P; Zhang TD; Chen SJ; Chen Z; Wang ZY
Blood; 1997 May; 89(9):3354-60. PubMed ID: 9129042
[TBL] [Abstract][Full Text] [Related]
22. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
23. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
24. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA
Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030
[TBL] [Abstract][Full Text] [Related]
25. [Arsenic efficient in acute promyelocytic leukemia].
Lehmann S; Paul C
Lakartidningen; 1999 Dec; 96(50):5626-8. PubMed ID: 10643228
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Tallman MS
Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161
[No Abstract] [Full Text] [Related]
27. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
28. QT prolongation: a case of arsenical pericardial and pleural effusion.
Vizzardi E; Zanini G; Antonioli E; D'Aloia A; Raddino R; Cas LD
Cardiovasc Toxicol; 2008 Mar; 8(1):41-4. PubMed ID: 18084726
[TBL] [Abstract][Full Text] [Related]
29. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang Z; Zhou J; Lu X; Gong Z; Le XC
Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
[TBL] [Abstract][Full Text] [Related]
30. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
31. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
32. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide for the treatment of acute promyelocytic leukemia.
Lam MS; Ignoffo RJ
Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303
[No Abstract] [Full Text] [Related]
34. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Au WY; Kumana CR; Lam CW; Cheng VC; Shek TW; Chan EY; Liu R; Kwong YL
Leuk Res; 2007 Jan; 31(1):105-8. PubMed ID: 16725199
[TBL] [Abstract][Full Text] [Related]
35. Arsenic trioxide - An old drug rediscovered.
Emadi A; Gore SD
Blood Rev; 2010; 24(4-5):191-9. PubMed ID: 20471733
[TBL] [Abstract][Full Text] [Related]
36. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
37. [Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Ercilla Liceaga M; Andueza Granados K; Fernández González I; Barcia Romero MJ
Farm Hosp; 2003; 27(2):93-100. PubMed ID: 12717564
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide: an ancient drug revived.
Zhou J
Chin Med J (Engl); 2012 Oct; 125(19):3556-60. PubMed ID: 23044323
[TBL] [Abstract][Full Text] [Related]
39. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
